The nation of Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) spanning five years due to the United States' insistence on sensitive data.
This move came to light following a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesperson later explained that the United States was requesting biological samples for research and commercial gain but refused to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further negotiations to reach a deal acceptable to all parties so the country's vital HIV programme can be sustained.
Broader Context
This development comes after a comparable situation in Kenya, where a high court suspended a related health funding agreement after legal challenges were raised about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per reports, Sixteen nations in Africa have so far signed these new health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data for a long time, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"In essence, our nation would supply the raw materials for scientific discovery with no assurance that the final treatments would be available to our citizens if a future disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending systems previously established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that honours the independence and dignity of both nations."
Medical Community Reaction
Medical experts said it recognised the government's concerns, but urged that talks must proceed since much of the country's Aids initiatives were funded by international support.
"If specific concerns arise, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
The halted deal highlights the continuing tensions between receiving crucial foreign assistance and protecting national sovereignty in an increasingly interconnected world.